Physician profile
Daniel A Friedman
NPI 1447335666
$12,218.98
in general payments reported to CMS, 2019-2025
45 companies · $2,174 in 2025
The $2,174 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $597 · 2021: $1,266 · 2022: $1,390 · 2023: $3,521 · 2024: $2,514 · 2025: $2,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,626 · Travel and Lodging: $2,552 · Education: $31.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,625.81 |
| Travel and Lodging | $2,551.77 |
| Education | $31.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,778.11 | 2019-2025 | |
| Abbott Laboratories | $2,551.77 | 2023-2024 | Flexability, Tacticath Ablation Catheter, Sensor Enabled |
| Janssen Biotech, INC. | $891.64 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $702.51 | 2019-2025 | Entyvio |
| Pfizer INC. | $506.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $382.58 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $335.05 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.28 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $289.14 | 2024-2025 | Voquezna |
| Celgene Corporation | $259.89 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $242.74 | 2023-2025 | Omvoh |
| Genzyme Corporation | $233.53 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $166.70 | 2020-2025 | Ocaliva |
| Ardelyx, INC. | $148.51 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $148.16 | 2019-2024 | Sucraid, Sucraid |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.